Safety and efficacy of intensity-modulated radiotherapy in the management of spermatic cord sarcoma - Université de Bourgogne Accéder directement au contenu
Article Dans Une Revue Cancer/Radiothérapie Année : 2017

Safety and efficacy of intensity-modulated radiotherapy in the management of spermatic cord sarcoma

Résumé

Purpose. - Spermatic cord sarcoma is a rare disease, which management remains controversial due to the lack of guidelines. The standard therapeutic approach is surgical: wide soft-tissue resection with radical inguinal orchidectomy, The diagnosis is made during the analysis of the specimen. The high rate of local recurrence indicates adjuvant radiotherapy of the tumor bed. The aim of this series is to determine the efficacy and safety of postoperative intensity-modulated radiotherapy for spermatic cord sarcomas. Patients and methods. - Our series included five consecutive cases of spermatic cord sarcoma treated between 2011 and 2014. The indications for radiotherapy were: R1 status after initial surgery, R1 status after wide en bloc resection and orchiectomy, high French federation of cancer centers (FNCLCC) grade, tumor size over 5 cm, tumor resection during surgery. Results. - Median age at diagnosis was 66 years (range 46-84 years). Median follow-up was 18 months (range 6-28 months). Four patients had repeat surgery after incomplete removal. All surgeries were orchidectomy with primary ligation of testicular vessels. One patient did not have an in sano margin after the second surgical procedure. The median tumor size was 60 mm (range 30-150 mm). No recurrence was observed during the follow-up. Conclusion. - No grade 4 toxicities were reported and the most frequent acute toxicity was dermatitis. No recurrence was reported after adjuvant intensity-modulated radiotherapy. The treatment is feasible and well tolerated and seems to provide encouraging results regarding locoregional control of the disease. Dynamic or rotational intensity-modulated radiotherapy is now recommended to decrease acute toxicities while improving the efficacy of this approach. (C) 2016 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.
Fichier non déposé

Dates et versions

hal-01516063 , version 1 (28-04-2017)

Identifiants

Citer

T. Cerda, É. Martin, G. Truc, G. Créhange, P. Maingon. Safety and efficacy of intensity-modulated radiotherapy in the management of spermatic cord sarcoma. Cancer/Radiothérapie, 2017, 21 (1), pp.16 - 20. ⟨10.1016/j.canrad.2016.07.102⟩. ⟨hal-01516063⟩
91 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More